Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2012. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the Deferred Annual Bonus Plan (DABP) post-tax awards for the 2011 bonus year.
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity figures for the company. Instead, it details specific performance thresholds used for executive compensation vesting:
- Adjusted Free Cash Flow Thresholds: Vesting begins at £17.30 billion (25% vesting), reaches 50% at £17.84 billion, 75% at £19.62 billion, and maximum vesting at £20.52 billion.
- Share Price: Co-Investment Shares were acquired at an Ordinary Share price of £14.025 on March 30, 2012.
Material Changes
The filing does not disclose material changes to the company's financial position or operations compared to prior periods. It reports a specific transaction where Mr. M. Dunoyer elected to participate in the DABP on a post-tax basis, acquiring 2,974 Ordinary Shares underlying Co-Investment Shares.
Guidance, Outlook, and Risks
Performance Measures: The DABP Matching Award vesting is subject to four equally weighted performance measures over the period of January 1, 2012, to December 31, 2014:
- Total Shareholder Return (TSR): Relative performance against a comparator group of 10 global pharmaceutical companies. No vesting occurs below the median; 30% vests at the median, rising to 100% at the upper quartile.
- Adjusted Free Cash Flow: Specific monetary thresholds apply as noted above.
- R&D New Product: Targets are undisclosed due to commercial sensitivity. Vesting ranges from 25% at threshold to 100% at 122% of the threshold.
- Business Diversification: Targets are undisclosed due to commercial sensitivity. Vesting ranges from 25% at threshold to 100% at 114% of the threshold.
Risks and Contingencies: If performance thresholds are not met, the conditional awards will lapse. Dividends accrue on deferred shares but only vest if the underlying Matching Awards vest.
Investor Verification Checklist
- Verify the final vesting outcomes for the 2012-2014 performance period once disclosed.
- Confirm the specific undisclosed targets for R&D new product and business diversification measures at the end of the performance period.
- Monitor the company's Adjusted Free Cash Flow against the £17.30 billion to £20.52 billion vesting range.
- Review the relative TSR performance against the specified comparator group (Abbott, AstraZeneca, BMS, Eli Lilly, J&J, Merck, Novartis, Pfizer, Roche, Sanofi).